Tellme's original business was operating hair salons. Over years of observing changes in their clientele, and as a service for customers who could no longer visit the salon due to illness or aging, the company developed a technology to assess the risk of glycation (a measure of aging) through hair analysis. This technology is currently being promoted as a diabetes screening technology. After being featured at the World Expo, it gained significant attention from overseas countries and institutions for its ability to assess risk without the need for blood sampling. In Japan, the technology is also seen as contributing to behavioral change among the segment of the population indifferent to their own health (kenko mukanshinsō) within local municipalities. Tellme is now pursuing the commercialization of this service as a means of optimizing social security costs.
A startup using regenerative medicine technologies to produce and supply homogeneous, high-precision blood cells at scale. It streamlines infectious disease research and the evaluation of pharmaceuticals and functional materials for efficacy and safety, while also providing research cells, testing cells, and diagnostic kits.
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
The heart is an organ upon which life itself depends. With a commitment to providing new treatment options for heart failure and saving many lives, iHeart Japan is developing regenerative medicine products using iPS cells. Our product, IHJ-301, combines cells derived from iPS cells, including cardiomyocytes and endothelial cells, with a biomaterial, enabling long-term survival following implantation onto the heart and is expected to deliver strong therapeutic efficacy. Going forward, we plan to commercialize this product in Japan and internationally, with the aim of realizing a society in which patients can be saved without heart transplantation.
BEL, Inc. is a deep-tech company specializing in materials science and surface engineering, focusing on the development and social implementation of advanced functional surfaces with antibacterial, antiviral, and anti-biofilm properties. The company integrates polymer science, additive manufacturing (3D printing), and surface microstructure control to create next-generation functional coatings for applications in medical devices, infrastructure, environmental systems, and marine environments. BEL actively promotes international collaboration with universities, research institutes, and industrial partners, aiming to advance materials innovation by integrating materials science with digital technologies such as data science and digital twin methodologies.